Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting
Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting
Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…Abstract Number: 729 • 2017 ACR/ARHP Annual Meeting
Clinically Relevant Serum Proteins in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS), an 11 center US cohort study of early diffuse cutaneous systemic sclerosis (dcSSc) patients, was designed…Abstract Number: 730 • 2017 ACR/ARHP Annual Meeting
The Association of Pulmonary Hypertension with Isolated Nucleolar Serum Autoantibodies in Systemic Sclerosis
Background/Purpose: Serum antibodies are used to identify SSc patients who may be at higher risk for SSc-PH. The Pulmonary Hypertension Assessment and Recognition of Outcomes…Abstract Number: 731 • 2017 ACR/ARHP Annual Meeting
Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis
Background/Purpose: No data are available to distinguish between progressive and stable patients when mild lung fibrosis is diagnosed in systemic sclerosis (SSc) patients. This study…Abstract Number: 732 • 2017 ACR/ARHP Annual Meeting
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Background/Purpose: Previously, we have identified short disease duration (≤15 months) and low baseline modified Rodnan skin score (mRSS) (≤22/51) as independent predictors of progressive skin…Abstract Number: 733 • 2017 ACR/ARHP Annual Meeting
Ethnic Variation in Systemic Sclerosis Morbidity and Mortality
Background/Purpose: Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by pathological skin thickening and can involve multiple internal organs. Ethnic variations in SSc…Abstract Number: 734 • 2017 ACR/ARHP Annual Meeting
Correlation of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis with Serum Biomarkers of Fibrogenesis in an Observational Cohort
Background/Purpose: The CRISS is a composite index of response in diffuse cutaneous systemic sclerosis (dcSSC). It is a 2-step process for the probability of improvement…Abstract Number: 735 • 2017 ACR/ARHP Annual Meeting
Cardiopulmonary Exercise Testing to “Detect” Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading death causes in SSc patients. To gain a better prognosis, screening methods are needed to…Abstract Number: 736 • 2017 ACR/ARHP Annual Meeting
N-Terminal Pro-Brain Natriuretic Peptide Is Disproportionately Elevated in Scleroderma Associated Pulmonary Arterial Hypertension Compared to Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: N-Terminal pro-brain natriuretic peptide (NT-proBNP) level tends to correlate with myocardial wall stress and/or myocardial damage (fibrosis). Hence, it has been promoted as a…Abstract Number: 737 • 2017 ACR/ARHP Annual Meeting
Dynamic Prediction of Pulmonary Hypertension Development in Systemic Sclerosis Patients Using Landmark Analysis – Comparison of Two Models
Background/Purpose: Pulmonary hypertension (PH) contributes substantially to systemic sclerosis (SSc)-related morbidity and mortality. It tends to develop later in the disease, creating an opportunity for…Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…Abstract Number: 739 • 2017 ACR/ARHP Annual Meeting
How Effective Is the Home Exercise Program for Hands in Patients with Systemic Sclerosis: Preliminary Results from a Randomized Controlled, Single-Blind, Clinical Trial
Background/Purpose: Systemic sclerosis (SSc) represents a heterogeneous autoimmune disease characterized by fibrosis of skin and internal organs. In particular, thickening of the skin, puffy hands,…Abstract Number: 740 • 2017 ACR/ARHP Annual Meeting
Prediction of Fibrosis Progression in Systemic Sclerosis By Collagen Biomarkers
Background/Purpose: Altered extracellular matrix (ECM) remodeling leading to fibrosis is a key pathogenic process in systemic sclerosis (SSc). We previously showed that collagen formation and…Abstract Number: 741 • 2017 ACR/ARHP Annual Meeting
Cardiac MRI in Systemic Sclerosis As Prognostic Tool of Cardiac Mortality in Symptomatic Patients
Background/Purpose: Cardiac involvement is a relevant prognostic determinant of outcome in Systemic Sclerosis (SSc). Since the role of cardiac MRI (CMR) is still uncertain, we…